Word: merck
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
White said that before the project was completed, Fogel went to work for the pharmaceutical giant, Merck...
...from the Rockefeller scientists' research will not be easy, and it certainly will not be quick. Still, this work is "identifying possible targets in the virus, and that's really the exciting part of it," says Dr. Adel Mahmoud, a lecturer at Princeton University and the former head of Merck Vaccines, the company that created the most promising HIV-vaccine candidate to date, which ultimately failed in clinical trials in 2007. (That drug, V520, used a common-cold virus to ferry three synthetic HIV genes into the body to trigger cell-mediated immunity. It was tested in several thousand people...
...Today there are a few other candidates in early phase trials, including compounds of two previously tested candidates, just in case they turn out to be effective together where each failed individually. Since Merck's setback in 2007, however, some scientists have questioned current vaccine-development tactics. And some researchers, including those in Nussenzweig's lab, are now trying to produce HIV immunity through antibodies; but despite good results in primates, they have had no luck so far in humans with a single-antibody vaccine...
...There's always been reason to worry about the influence of Big Pharma on the practice of medicine. When doctors are being lavished with meals and speaking fees by the likes of Pfizer and Merck, can you really trust them when they later write prescriptions for those companies' drugs? Medical schools were long considered above such vulgar stuff. Now, however, it turns out that many professors and instructors are, legally, on the dole as well, and students are beginning to worry that what they're being taught is just as one-sided as what patients are being prescribed. Campaigns...
After 20 years at Harvard Medical School, Professor D. Gary Gilliland will depart to lead cancer research at the pharmaceutical giant, Merck & Co., the company announced earlier this week. While at Harvard, Gilliland gained international recognition for discovering the genetic basis of leukemia and served as director of both the Leukemia Program at the Dana-Farber/Harvard Cancer Center and the Cancer Stem Cell Program for the Harvard Stem Cell Institute. Gilliland’s latest work harnessed his earlier findings to explore how drugs could be used to treat leukemia. “His expertise in both basic...